B-Cell Maturation Antigens (BCMA) Bispecific Antibody, Teclistamab+Daratumumab, 1,2,3 prior line of therapy, Lenalidomide Refractory, Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Lenalidomide Exposed, Daratumumab+Pomalidomide+Dexamethasone (DPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd)
### Instruction:
Identify the study with the following condition. 
### Input:
B-Cell Maturation Antigens (BCMA) Bispecific Antibody, Teclistamab+Daratumumab, 1,2,3 prior line of therapy, Lenalidomide Refractory, Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Lenalidomide Exposed, Daratumumab+Pomalidomide+Dexamethasone (DPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd) 
### Output:
Popular Name is MajesTEC-3, Study ID is NCT05083169